Sustanon"250" injektioneste, liuos Finlandiya - Fince - Fimea (Suomen lääkevirasto)

sustanon"250" injektioneste, liuos

aspen pharma trading limited - testosterone decanoate, testosterone isocaproate, testosterone phenylpropionate, testosterone propionate - injektioneste, liuos - testosteroni

Betadine 75 mg/ml ihonpuhdisteliuos Finlandiya - Fince - Fimea (Suomen lääkevirasto)

betadine 75 mg/ml ihonpuhdisteliuos

orifarm healthcare a/s - polyvidone-iodine - ihonpuhdisteliuos - 75 mg/ml - povidonijodi

Betadine 100 mg/ml paikallisantiseptiliuos Finlandiya - Fince - Fimea (Suomen lääkevirasto)

betadine 100 mg/ml paikallisantiseptiliuos

orifarm healthcare a/s - polyvidone-iodine - paikallisantiseptiliuos - 100 mg/ml - povidonijodi

Betadine 100 mg/g voide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

betadine 100 mg/g voide

orifarm healthcare a/s - polyvidone-iodine - voide - 100 mg/g - povidonijodi

Betadine 10 mg/ml suuvesi Finlandiya - Fince - Fimea (Suomen lääkevirasto)

betadine 10 mg/ml suuvesi

orifarm healthcare a/s - polyvidone-iodine - suuvesi - 10 mg/ml - muut

Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) Avrupa Birliği - Fince - EMA (European Medicines Agency)

chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau)

leadiant gmbh - chenodeoxycholic happo - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile- ja maksanhoito - chenodeoxycholic happo on tarkoitettu kohtelu synnyn ensisijainen sappihappoja synteesi johtuu sterolien 27 hydroksylaasin puutos (esitetään kuin cerebrotendinous xanthomatosis (jari)) pikkulapsilla, lapset ja nuoret vuotiaat 1 kuukausi – 18-vuotiaat ja aikuiset.

Trodelvy Avrupa Birliği - Fince - EMA (European Medicines Agency)

trodelvy

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastiset aineet - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Genvoya Avrupa Birliği - Fince - EMA (European Medicines Agency)

genvoya

gilead sciences ireland uc - elvitegravir, cobicistat, emtrisitabiini, tenofoviiri alafenamide - hiv-infektiot - antiviraalit systeemiseen käyttöön - genvoya on tarkoitettu aikuisille ja nuorille (alle 12-vuotiaat ja vanhemmat kanssa kehon paino 35 kg) tartunnan immuunikatoviruksen (hiv 1) 1 ilman mitään tunnettujen mutaatioiden liittyvät vastustuskyky integraasientsyymin-estäjiin hoidossa emtricitabine tai yhdistelmä.

Descovy Avrupa Birliği - Fince - EMA (European Medicines Agency)

descovy

gilead sciences ireland uc - emtrisitabiinin, tenofoviirin alafenamide - hiv-infektiot - antiviraalit systeemiseen käyttöön - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Zydelig Avrupa Birliği - Fince - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.